Yael Mossé Laboratory
Studies are assessing the safety and efficacy of the ALK inhibitor crizotinib in children with refractory and relapsed neuroblastoma and looking for ways to improve the response to crizotinib.
The presence of ALK on neuroblastoma cells, but not normal tissue cells, makes it a promising target for immunotherapeutic intervention.
Molecular profiling of tumors from patients with relapsed or refractory neuroblastoma may help determine more rational treatment options.
Researchers are currently enrolling patients for this Phase III trial assessing the addition of the radiopharmaceutical MIBG to standard care for high-risk neuroblastoma.